Yikun Xingjian Biomedical

Yikun Xingjian Biomedical is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative small molecule drugs targeting the innate immune system. The company focuses on the discovery and development of Toll-like receptor (TLR) and STING agonists designed to treat solid tumors and chronic viral infections such as Hepatitis B. Its lead programs include TLR7/8 dual agonists and STING agonists that aim to activate the body's natural immune response to achieve therapeutic efficacy. Yikun Xingjian leverages a proprietary drug discovery platform to optimize the safety and potency of its innate immune modulators.